eBook: Rare Disease Biotech Landscape, 2026
Summary
Rare disease demands a unique playbook: The patient journey is rarely linear, the evidence base is often limited, and “rare” can have different meanings across settings and geographies. The third edition of our annual rare disease eBook explores the unique dynamics of the rare disease landscape and its implications for biotech stakeholders.Rare diseases are not so rare. This is a commonly used phrase in the rare disease community. There are more than 10,000 known rare conditions that affect more than 30 million Americans and more than 400 million people worldwide.
This diverse and complex disease area poses challenges not only to patients but also to their caregivers, regulators, pharmaceutical manufacturers, policymakers, and other stakeholders. Given that fewer than 10% of these conditions have any available treatment options, there is a significant unmet need in this space.
In this edition of the eBook, Avalere Health’s Advisory experts describe their first-hand experience with the rare disease sector, identify regulatory avenues and mechanisms for manufacturers to pursue when developing treatments for rare disease, provide an overview of evidence generation strategies to fill data gaps that are inherent to small patient population numbers, and dive into niche topics, such as gene therapy stewardship across healthcare systems and multistakeholder collaboration to drive access in Asia-Pacific.
Download the eBook and watch a replay of our recent webinar, “Voices that move systems.”
Services
produces measurable results. Let's work together.
